Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast

Table 4

Age- and multivariable-adjusted OR (95% CI) for associations between baseline level of IGFBP-2 and risk of atypical hyperplasia of the breast after stratification by hormone therapy (HT) use.

IGFBP-2 (µIU/mL)	Co/Ca	Model 1 OR^a	Model 2 OR^b	Co/Ca	Model 3 OR^c
Nonusers of HT
Q1	28/38	1.0^Ref.	1.0^Ref.	25/35	1.0^Ref.
Q2	42/25	0.44 (0.21–0.95)	0.47 (0.20–1.08)	38/22	0.48 (0.20–1.15)
Q3	43/45	0.65 (0.32–1.33)	0.72 (0.33–1.60)	40/41	0.66 (0.29–1.52)
Q4	47/31	0.40 (0.19–0.83)	0.38 (0.15–0.93)	47/30	0.33 (0.13–0.86)
Trend		0.06	0.11		0.06
Unopposed estrogen users
Q1	24/20	1.0^Ref.	1.0^Ref.	22/19	1.0^Ref.
Q2	11/19	2.16 (0.78–5.99)	2.51 (0.87–7.23)	8/17	2.42 (0.81–7.21)
Q3	12/12	1.11 (0.38–3.24)	1.27 (0.42–3.89)	12/12	1.12 (0.36–2.49)
Q4	12/11	0.67 (0.21–2.15)	1.54 (0.42–5.62)	12/11	1.37 (0.37–5.06)
Trend		0.28	0.79		0.94
Estrogen plus progestin users
Q1	17/19	1.0^Ref.	1.0^Ref.	16/17	1.0^Ref.
Q2	16/25	1.60 (0.64–3.98)	2.06 (0.79–5.38)	15/25	2.00 (0.76–5.25)
Q3	14/21	1.26 (0.45–3.52)	1.43 (0.48–4.28)	14/21	1.41 (0.47–4.24)
Q4	9/9	1.00 (0.30–3.31)	1.37 (0.38–5.00)	9/9	1.29 (0.35–4.75)
Trend		0.70	0.91		0.85

Model 1 adjusted for age and BMI (<25, 25–<30, 30–<35, ≥35 kg/m²).
Model 2 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol.
Model 3 additionally adjusted for serologic level of insulin, adiponectin, C-reactive protein, and tertile of estradiol and restricted to those without a history of diabetes.